PYC Therapeutics Advances Clinical Trials for PKD Treatment

PYC Therapeutics Limited ( (AU:PYC) ) has shared an announcement.

PYC Therapeutics Limited has announced the progression of its clinical trials for PYC-003, a drug candidate for Polycystic Kidney Disease (PKD). The Safety Review Committee has approved the escalation to the highest dose cohort in the Single Ascending Dose study, and dosing has commenced for PKD patients in Part B of the study. This advancement positions PYC to proceed to repeat dose studies in late 2025, potentially leading to a Phase 2/3 trial to support a New Drug Application.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a precision medicine company focused on developing treatments for genetic diseases with no current treatment options. The company is engaged in three clinical-stage drug development programs, including PYC-003, which targets the underlying cause of Polycystic Kidney Disease (PKD).

Average Trading Volume: 544,501

Technical Sentiment Signal: Buy

Current Market Cap: A$699.9M

Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.